Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Science 23 March 2001:
Vol. 291. no. 5512, pp. 2340 - 2341
DOI: 10.1126/science.291.5512.2340b
Prev | Table of Contents | Next

News

After the Fall

Robert F. Service

In the early 1990s, two start-ups pushed new sugar-based drugs into late-stage clinical trials that promised to usher in a new era of compounds targeting sugars and sugar-binding proteins, which together play key roles in infections, cancer metastasis, and immune system diseases. But both drugs faltered, souring many investors and major pharmaceutical companies on the idea that sugars would make good drugs. Now carbohydrate specialists say biotech companies and a few venturesome pharmaceutical giants are regaining a bit of a sweet tooth.

Read the Full Text

To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)